CASI Pharmaceuticals (CASI) Competitors $1.95 +0.66 (+51.16%) Closing price 04:00 PM EasternExtended Trading$1.92 -0.03 (-1.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CASI vs. AVTX, BRNS, MNOV, CELU, ASRT, INCR, IRD, GNTA, ATRA, and IMAShould you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Avalo Therapeutics (AVTX), Barinthus Biotherapeutics (BRNS), MediciNova (MNOV), Celularity (CELU), Assertio (ASRT), InterCure (INCR), Opus Genetics (IRD), Genenta Science (GNTA), Atara Biotherapeutics (ATRA), and Ikena Oncology (IMA). These companies are all part of the "pharmaceutical products" industry. CASI Pharmaceuticals vs. Its Competitors Avalo Therapeutics Barinthus Biotherapeutics MediciNova Celularity Assertio InterCure Opus Genetics Genenta Science Atara Biotherapeutics Ikena Oncology CASI Pharmaceuticals (NASDAQ:CASI) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Do analysts rate CASI or AVTX? CASI Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 105.13%. Avalo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 234.45%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than CASI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CASI or AVTX? In the previous week, Avalo Therapeutics had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Avalo Therapeutics and 0 mentions for CASI Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 0.51 beat CASI Pharmaceuticals' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment CASI Pharmaceuticals Neutral Avalo Therapeutics Positive Is CASI or AVTX more profitable? Avalo Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Avalo Therapeutics' return on equity of 111.00% beat CASI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals-129.05% -972.55% -77.33% Avalo Therapeutics N/A 111.00%58.88% Which has more risk & volatility, CASI or AVTX? CASI Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Do institutionals & insiders hold more shares of CASI or AVTX? 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, CASI or AVTX? Avalo Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCASI Pharmaceuticals$28.54M0.84-$39.26M-$2.55-0.76Avalo Therapeutics$440K220.78-$35.13MN/AN/A SummaryAvalo Therapeutics beats CASI Pharmaceuticals on 11 of the 13 factors compared between the two stocks. Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CASI vs. The Competition Export to ExcelMetricCASI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.86M$2.50B$5.52B$9.36BDividend YieldN/A1.78%4.73%4.15%P/E Ratio-0.763.6918.8122.61Price / Sales0.84711.32452.86109.43Price / CashN/A22.2824.4827.20Price / Book16.255.008.525.77Net Income-$39.26M$31.61M$3.24B$264.99M7 Day Performance20.37%-3.00%-0.79%-2.13%1 Month Performance46.62%5.68%8.00%7.06%1 Year Performance-70.85%0.43%27.38%20.80% CASI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CASICASI Pharmaceuticals3.9698 of 5 stars$1.95+51.2%$4.00+105.1%-80.7%$15.86M$28.54M-0.76180News CoverageGap UpHigh Trading VolumeAVTXAvalo Therapeutics2.9074 of 5 stars$6.58-1.6%$30.00+355.9%-26.9%$72.44M$440K0.0040News CoverageUpcoming EarningsBRNSBarinthus Biotherapeutics2.027 of 5 stars$1.55-13.4%$6.25+303.2%-1.7%$72.21M$14.97M-0.95107Upcoming EarningsMNOVMediciNova2.7305 of 5 stars$1.45-0.7%$7.00+382.8%+10.9%$71.61M$1M-6.3010Upcoming EarningsGap UpHigh Trading VolumeCELUCelularity0.2769 of 5 stars$3.29+11.1%N/A+3.1%$70.89M$54.22M-1.24220News CoverageUpcoming EarningsAnalyst UpgradeASRTAssertio1.8685 of 5 stars$0.73-2.0%$2.63+262.1%-44.8%$70.88M$124.96M-2.2720Upcoming EarningsINCRInterCureN/A$1.51-2.6%N/A-31.1%$70.64M$66.28M0.00350Gap UpIRDOpus Genetics1.1871 of 5 stars$1.20+1.7%$7.33+511.1%N/A$70.40M$10.99M-0.5714Gap UpGNTAGenenta Science2.3232 of 5 stars$3.75-0.8%$25.00+566.5%-7.5%$69.14MN/A0.007News CoveragePositive NewsShort Interest ↑ATRAAtara Biotherapeutics3.8253 of 5 stars$11.81+2.0%$20.00+69.3%+27.3%$69.03M$128.94M-3.17330Upcoming EarningsIMAIkena Oncology3.4648 of 5 stars$1.48+8.0%$35.50+2,298.6%-12.7%$69.01M$9.16M-2.31780Positive NewsStock SplitAnalyst Revision Related Companies and Tools Related Companies Avalo Therapeutics Competitors Barinthus Biotherapeutics Competitors MediciNova Competitors Celularity Competitors Assertio Competitors InterCure Competitors Opus Genetics Competitors Genenta Science Competitors Atara Biotherapeutics Competitors Ikena Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CASI) was last updated on 8/4/2025 by MarketBeat.com Staff From Our Partners[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CASI Stock Alerts